Arcus Biosciences, INC Form 4 insider transactions

Arcus Biosciences CEO Terry J. Rosen sold 54,691 shares of common stock over two days in December 2025 to cover tax withholding obligations related to RSU vesting, not as a discretionary trade.

Arcus Biosciences President Juan C. Jaen sold 82,997 shares of common stock for a weighted average price of $24.7069 per share.

Arcus Biosciences Chief Accounting Officer Alexander Azoy exercised options and sold 1,900 shares of common stock under a 10b5-1 plan.

Arcus Biosciences CFO Robert C. Goeltz II sold 5,000 shares of common stock for $25 per share on November 26, 2025, under a pre-arranged 10b5-1 trading plan.

Arcus Biosciences President Juan C. Jaen sold a total of 50,000 shares of common stock in multiple transactions under a Rule 10b5-1 trading plan.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold 50,291 shares of common stock on November 7, 2025, following the exercise of stock options, as part of a pre-arranged 10b5-1 trading plan.

Arcus Biosciences President Juan C. Jaen sold 4,314 shares of common stock for approximately $20.32 per share under a pre-arranged trading plan.

Arcus Biosciences President Juan C. Jaen reported the sale of 96,859 shares of common stock in late October 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold 5,000 shares of common stock for $20 per share as part of a pre-arranged trading plan.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, exercised stock options and subsequently sold 50,292 shares of common stock under a Rule 10b5-1 trading plan.

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 2,831 shares of common stock at $13 per share, pursuant to a Rule 10b5-1 trading plan.

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 1,579 shares of common stock for approximately $11.88 per share under a pre-arranged 10b5-1 trading plan.

Arcus Biosciences, Inc. Director David L. Lacey was granted 13,300 restricted stock units and 38,300 stock options on June 10, 2025, as detailed in a recent SEC Form 4 filing.

Andrew Perlman, a Director at Arcus Biosciences, Inc., was granted 13,300 restricted stock units and options to purchase 38,300 shares of common stock, aligning his interests with long-term shareholder value.

Arcus Biosciences, Inc. Director Kathryn Falberg reported the acquisition of 13,300 restricted stock units and 38,300 stock options on June 10, 2025, as part of her compensation.

Arcus Biosciences, Inc. Director Patrick Machado was granted 13,300 restricted stock units and 38,300 stock options, aligning his interests with shareholders.

Arcus Biosciences, Inc. Director Antoni Ribas was granted 13,300 restricted stock units and options to purchase 38,300 shares of common stock, aligning his interests with shareholders.

Arcus Biosciences, Inc. Director Yasunori Kaneko was granted 13,300 restricted stock units and options to purchase 38,300 shares of common stock, aligning his interests with shareholders.

Arcus Biosciences, Inc. Director Nicole Lambert was granted 13,300 restricted stock units and options to purchase 38,300 shares of common stock, aligning her interests with shareholders.

Director Yasunori Kaneko of Arcus Biosciences, Inc. [RCUS] recently purchased 20,000 shares of common stock at an average price of $10.06.

Arcus Biosciences CEO Terry J. Rosen purchased 19,800 shares of RCUS stock at an average price of $10.175 per share on February 27, 2025.

Gilead Sciences, Inc. reports acquiring 1,363,636 shares of Arcus Biosciences, Inc. at $11 per share, increasing its holdings to 31,424,760 shares.

Richard Markus, Chief Medical Officer of Arcus Biosciences, reports the acquisition of restricted stock units and stock options.

Arcus Biosciences' General Counsel, Carolyn C. Tang, was granted 150,000 stock options and 37,000 restricted stock units on January 23, 2025.

Arcus Biosciences CEO Terry Rosen was granted 165,000 restricted stock units and options to purchase 650,000 shares of common stock.

Arcus Biosciences director Antoni Ribas acquired 5,000 stock options and disposed of 30,350 common shares in a recent transaction.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, was granted 200,000 stock options and 50,000 restricted stock units on January 23, 2025.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, was granted 150,000 stock options and 37,000 restricted stock units on January 23, 2025.

Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, reports the acquisition of restricted stock units and stock options.

Director David L. Lacey acquired 5,000 stock options in Arcus Biosciences, Inc. on January 23, 2025.